

**Payment Allowance Limits for Medicare Part B Drugs**

**Effective October 1, 2013 through December 31, 2013**

**Note 1:** Payment allowance limits subject to the ASP methodology are based on 2Q13 ASP data.

**Note 2:** The absence or presence of a HCPCS code and the payment allowance limits in this table does not indicate Medicare coverage of the drug. Similarly, the inclusion of a payment allowance limit within a specific column does not indicate Medicare coverage of the drug in that specific category. These determinations shall be made by the local Medicare contractor processing the claim.

HCPCS Code	Short Description	HCPCS Code Dosage	Payment Limit	Vaccine AWP%	Vaccine Limit	Infusion AWP%	DME Infusion Limit	Blood AWP%	Blood limit	Clotting Factor	Notes
90371	Hep b ig, im	1 ML	112.029								
90375	Rabies ig, im/sc	150 IU	219.815								
90376	Rabies ig, heat treated	150 IU	216.535								
90385	Rh ig, minidose, im	50 MCG	25.281								
90585	Bcg vaccine, percut	50 MG	120.914								
90586	Bcg vaccine, intravesical	1 EACH	120.914								
90632	Hep a vaccine, adult im	1 ML	49.667								
90654	Flu vaccine, intradermal, no preserv	0.1 ML	18.918	95	18.918						
90655	Flu vaccine no preserv 6-35m, im	0.25 ML	17.243	95	17.243						
90656	Flu vaccine no preserv 3 yo & >, im	0.50 ML	12.398	95	12.398						
90657	Flu vaccine, 6-35 mo, im	0.25 ML	6.022	95	6.022						
90662	Flu vacc prsv free inc antig	0.5 ML	31.823	95	31.823						
90669	Pneumococcal vacc, 7 val im	0.5 ML	95.481	95	95.481						
90670	Pneumococcal vacc, 13 val im	0.5 ML	145.107	95	145.107						
90672	Flu vaccine 4 valent nasal	0.2 ml	24.596	95	24.596						Added October 2013
90675	Rabies vaccine, im	1 ML	232.385								
90685	Flu vac no prsv 4 val 6-35 m	0.25 mL	23.228	95	23.228						Added October 2013
90686	Flu vac no prsv 4 val 3 yrs+	0.5 ml	19.409	95	19.409						Added October 2013
90691	Typhoid vaccine, im	0.5 ML	62.552								
90703	Tetanus vaccine, im	0.5 ML	39.285								
90714	Td vaccine no prsrv >/= 7 yo, im	0.5 ML	19.474								
90715	Tdap >= 7 yo, im	0.5 ML	33.799								
90717	Yellow fever vaccine, sc	0.5 ML	75.060								
90732	Pneumococcal vaccine	0.5 ML	72.352	95	72.352						
90733	Meningococcal vaccine, sc	0.5 ML	106.492								
90735	Encephalitis vaccine, sc	1 ML	102.078								
90740	Hepb vacc, ill pat 3 dose im	40 MCG	119.415	95	119.415						
90743	Hep b vacc, adul, 2 dose, im	1 DOSE	24.216	95	24.216						
90744	Hepb vacc ped/adol 3 dose im	1 DOSE	24.216	95	24.216						
90746	Hep b vaccine, adult, im	20 MCG	59.708	95	59.708						
90747	Hepb vacc, ill pat 4 dose im	40 MCG	119.415	95	119.415						

## **Payment Allowance Limits for Medicare Part B Drugs**

**Effective October 1, 2013 through December 31, 2013**

**Note 1: Payment allowance limits subject to the ASP methodology are based on 2Q13 ASP data.**

**Note 2: The absence or presence of a HCPCS code and the payment allowance limits in this table does not indicate Medicare coverage of the drug. Similarly, the inclusion of a payment allowance limit within a specific column does not indicate Medicare coverage of the drug in that specific category. These determinations shall be made by the local Medicare contractor processing the claim.**

## **Payment Allowance Limits for Medicare Part B Drugs**

**Effective October 1, 2013 through December 31, 2013**

**Note 1: Payment allowance limits subject to the ASP methodology are based on 2Q13 ASP data.**

**Note 2: The absence or presence of a HCPCS code and the payment allowance limits in this table does not indicate Medicare coverage of the drug. Similarly, the inclusion of a payment allowance limit within a specific column does not indicate Medicare coverage of the drug in that specific category. These determinations shall be made by the local Medicare contractor processing the claim.**

## **Payment Allowance Limits for Medicare Part B Drugs**

**Effective October 1, 2013 through December 31, 2013**

**Note 1: Payment allowance limits subject to the ASP methodology are based on 2Q13 ASP data.**

**Note 2: The absence or presence of a HCPCS code and the payment allowance limits in this table does not indicate Medicare coverage of the drug. Similarly, the inclusion of a payment allowance limit within a specific column does not indicate Medicare coverage of the drug in that specific category. These determinations shall be made by the local Medicare contractor processing the claim.**

## **Payment Allowance Limits for Medicare Part B Drugs**

**Effective October 1, 2013 through December 31, 2013**

**Note 1: Payment allowance limits subject to the ASP methodology are based on 2Q13 ASP data.**

**Note 2: The absence or presence of a HCPCS code and the payment allowance limits in this table does not indicate Medicare coverage of the drug. Similarly, the inclusion of a payment allowance limit within a specific column does not indicate Medicare coverage of the drug in that specific category. These determinations shall be made by the local Medicare contractor processing the claim.**

## **Payment Allowance Limits for Medicare Part B Drugs**

**Effective October 1, 2013 through December 31, 2013**

**Note 1: Payment allowance limits subject to the ASP methodology are based on 2Q13 ASP data.**

**Note 2: The absence or presence of a HCPCS code and the payment allowance limits in this table does not indicate Medicare coverage of the drug. Similarly, the inclusion of a payment allowance limit within a specific column does not indicate Medicare coverage of the drug in that specific category. These determinations shall be made by the local Medicare contractor processing the claim.**

## **Payment Allowance Limits for Medicare Part B Drugs**

**Effective October 1, 2013 through December 31, 2013**

**Note 1: Payment allowance limits subject to the ASP methodology are based on 2Q13 ASP data.**

**Note 2: The absence or presence of a HCPCS code and the payment allowance limits in this table does not indicate Medicare coverage of the drug. Similarly, the inclusion of a payment allowance limit within a specific column does not indicate Medicare coverage of the drug in that specific category. These determinations shall be made by the local Medicare contractor processing the claim.**

## **Payment Allowance Limits for Medicare Part B Drugs**

**Effective October 1, 2013 through December 31, 2013**

**Note 1: Payment allowance limits subject to the ASP methodology are based on 2Q13 ASP data.**

**Note 2: The absence or presence of a HCPCS code and the payment allowance limits in this table does not indicate Medicare coverage of the drug. Similarly, the inclusion of a payment allowance limit within a specific column does not indicate Medicare coverage of the drug in that specific category. These determinations shall be made by the local Medicare contractor processing the claim.**

## **Payment Allowance Limits for Medicare Part B Drugs**

**Effective October 1, 2013 through December 31, 2013**

**Note 1: Payment allowance limits subject to the ASP methodology are based on 2Q13 ASP data.**

**Note 2: The absence or presence of a HCPCS code and the payment allowance limits in this table does not indicate Medicare coverage of the drug. Similarly, the inclusion of a payment allowance limit within a specific column does not indicate Medicare coverage of the drug in that specific category. These determinations shall be made by the local Medicare contractor processing the claim.**

## **Payment Allowance Limits for Medicare Part B Drugs**

**Effective October 1, 2013 through December 31, 2013**

**Note 1: Payment allowance limits subject to the ASP methodology are based on 2Q13 ASP data.**

**Note 2: The absence or presence of a HCPCS code and the payment allowance limits in this table does not indicate Medicare coverage of the drug. Similarly, the inclusion of a payment allowance limit within a specific column does not indicate Medicare coverage of the drug in that specific category. These determinations shall be made by the local Medicare contractor processing the claim.**

## **Payment Allowance Limits for Medicare Part B Drugs**

**Effective October 1, 2013 through December 31, 2013**

**Note 1: Payment allowance limits subject to the ASP methodology are based on 2Q13 ASP data.**

**Note 2: The absence or presence of a HCPCS code and the payment allowance limits in this table does not indicate Medicare coverage of the drug. Similarly, the inclusion of a payment allowance limit within a specific column does not indicate Medicare coverage of the drug in that specific category. These determinations shall be made by the local Medicare contractor processing the claim.**

## **Payment Allowance Limits for Medicare Part B Drugs**

**Effective October 1, 2013 through December 31, 2013**

**Note 1: Payment allowance limits subject to the ASP methodology are based on 2Q13 ASP data.**

**Note 2: The absence or presence of a HCPCS code and the payment allowance limits in this table does not indicate Medicare coverage of the drug. Similarly, the inclusion of a payment allowance limit within a specific column does not indicate Medicare coverage of the drug in that specific category. These determinations shall be made by the local Medicare contractor processing the claim.**

## **Payment Allowance Limits for Medicare Part B Drugs**

**Effective October 1, 2013 through December 31, 2013**

**Note 1: Payment allowance limits subject to the ASP methodology are based on 2Q13 ASP data.**

**Note 2: The absence or presence of a HCPCS code and the payment allowance limits in this table does not indicate Medicare coverage of the drug. Similarly, the inclusion of a payment allowance limit within a specific column does not indicate Medicare coverage of the drug in that specific category. These determinations shall be made by the local Medicare contractor processing the claim.**

**Payment Allowance Limits for Medicare Part B Drugs**

**Effective October 1, 2013 through December 31, 2013**

**Note 1:** Payment allowance limits subject to the ASP methodology are based on 2Q13 ASP data.

**Note 2:** The absence or presence of a HCPCS code and the payment allowance limits in this table does not indicate Medicare coverage of the drug. Similarly, the inclusion of a payment allowance limit within a specific column does not indicate Medicare coverage of the drug in that specific category. These determinations shall be made by the local Medicare contractor processing the claim.

HCPCS Code	Short Description	HCPCS Code Dosage	Payment Limit	Vaccine AWP%	Vaccine Limit	Infusion AWP%	DME Infusion Limit	Blood AWP%	Blood limit	Clotting Factor	Notes
J7631	Cromolyn sodium noncomp unit	10 MG	0.495								
J7639	Dornase alfa non-comp unit	1 MG	32.778								
J7644	Ipratropium bromide non-comp	1 MG	0.240								
J7665	Mannitol for inhaler	5 MG	0.669								
J7669	Metaproterenol non-comp unit	10 MG	0.435								
J7674	Methacholine chloride, neb	1 MG	0.494								
J7682	Tobramycin non-comp unit	300 MG	119.999								
J7686	Treprostинil, non-comp unit	1.74 MG	460.450								
J8501	Oral aprepitant	5 MG	6.688								
J8510	Oral busulfan	2 MG	11.029								
J8520	Capecitabine, oral, 150 mg	150 MG	9.687								
J8521	Capecitabine, oral, 500 mg	500 MG	32.191								
J8530	Cyclophosphamide oral 25 MG	25 MG	0.975								
J8540	Oral dexamethasone	0.25 MG	0.178								
J8560	Etoposide oral 50 MG	50 MG	55.677								
J8562	Oral fludarabine phosphate	10 MG	81.772								
J8600	Melphalan oral 2 MG	2 MG	8.734								
J8610	Methotrexate oral 2.5 MG	2.5 MG	1.082								
J8700	Temozolomide	5 MG	11.558								
J8705	Topotecan oral	0.25 mg	89.128								
J9000	Doxorubicin hcl injection	10 MG	3.473								
J9010	Alemtuzumab injection	10 MG	623.633								
J9017	Arsenic trioxide injection	1 MG	49.400								
J9019	Erwinaze injection	1,000 IU	344.378								
J9020	Asparaginase, NOS	10000 UNITS	64.565								
J9025	Azacitidine injection	1 MG	5.744								
J9027	Clofarabine injection	1 MG	129.525								
J9031	Bcg live intravesical vac	1 EA	120.914								
J9033	Bendamustine injection	1 MG	21.060								
J9035	Bevacizumab injection	10 MG	64.622								
J9040	Bleomycin sulfate injection	15 UNITS	21.044		95	289.370					

## **Payment Allowance Limits for Medicare Part B Drugs**

**Effective October 1, 2013 through December 31, 2013**

**Note 1: Payment allowance limits subject to the ASP methodology are based on 2Q13 ASP data.**

**Note 2: The absence or presence of a HCPCS code and the payment allowance limits in this table does not indicate Medicare coverage of the drug. Similarly, the inclusion of a payment allowance limit within a specific column does not indicate Medicare coverage of the drug in that specific category. These determinations shall be made by the local Medicare contractor processing the claim.**

**Payment Allowance Limits for Medicare Part B Drugs**

**Effective October 1, 2013 through December 31, 2013**

**Note 1:** Payment allowance limits subject to the ASP methodology are based on 2Q13 ASP data.

**Note 2:** The absence or presence of a HCPCS code and the payment allowance limits in this table does not indicate Medicare coverage of the drug. Similarly, the inclusion of a payment allowance limit within a specific column does not indicate Medicare coverage of the drug in that specific category. These determinations shall be made by the local Medicare contractor processing the claim.

HCPCS Code	Short Description	HCPCS Code Dosage	Payment Limit	Vaccine AWP%	Vaccine Limit	Infusion AWP%	DME Infusion Limit	Blood AWP%	Blood limit	Clotting Factor	Notes
J9214	Interferon alfa-2b inj	1 MIL UNITS	20.695								
J9217	Leuprolide acetate suspnsion	7.5 MG	202.837								
J9218	Leuprolide acetate injecton	1 MG	10.250								
J9225	Vantas implant	50 MG	2966.802								
J9226	Supprelin LA implant	50 MG	16660.709								
J9228	Ipilimumab injection	1 MG	128.955								
J9230	Mechlorethamine hcl inj	10 MG	154.698								
J9245	Inj melphalan hydrochl 50 MG	50 MG	1293.550								
J9250	Methotrexate sodium inj	5 MG	0.255								
J9260	Methotrexate sodium inj	50 MG	2.498								
J9261	Nelarabine injection	50 MG	130.634								
J9263	Oxaliplatin	0.5 MG	0.535								
J9264	Paclitaxel protein bound	1 MG	9.553								
J9265	Paclitaxel injection	30 MG	4.348								
J9266	Pegasparagase injection	1 EA	6007.380								
J9268	Pentostatin injection	10 MG	1419.700								
J9280	Mitomycin injection	5 MG	24.535								
J9293	Mitoxantrone hydrochl / 5 MG	5 MG	34.619								
J9300	Gemtuzumab ozogamicin inj	5 MG	2742.591								
J9302	Ofatumumab injection	10 MG	46.530								
J9303	Panitumumab injection	10 MG	91.380								
J9305	Pemetrexed injection	10 MG	59.488								
J9307	Pralatrexate injection	1 MG	182.611								
J9310	Rituximab injection	100 MG	678.702								
J9315	Romidepsin injection	1 MG	251.936								
J9320	Streptozocin injection	1 GM	274.345								
J9328	Temozolomide injection	1 MG	5.027								
J9330	Tensirolimus injection	1 MG	55.970								
J9340	Thiotepa injection	15 MG	630.700								
J9351	Topotecan injection	0.1 MG	2.196								
J9355	Trastuzumab injection	10 MG	78.720		95	58.130					

## **Payment Allowance Limits for Medicare Part B Drugs**

**Effective October 1, 2013 through December 31, 2013**

**Note 1: Payment allowance limits subject to the ASP methodology are based on 2Q13 ASP data.**

**Note 2: The absence or presence of a HCPCS code and the payment allowance limits in this table does not indicate Medicare coverage of the drug. Similarly, the inclusion of a payment allowance limit within a specific column does not indicate Medicare coverage of the drug in that specific category. These determinations shall be made by the local Medicare contractor processing the claim.**

## **Payment Allowance Limits for Medicare Part B Drugs**

**Effective October 1, 2013 through December 31, 2013**

**Note 1: Payment allowance limits subject to the ASP methodology are based on 2Q13 ASP data.**

**Note 2: The absence or presence of a HCPCS code and the payment allowance limits in this table does not indicate Medicare coverage of the drug. Similarly, the inclusion of a payment allowance limit within a specific column does not indicate Medicare coverage of the drug in that specific category. These determinations shall be made by the local Medicare contractor processing the claim.**